Agios Pharmaceuticals (NASDAQ:AGIO) Shares Gap Up – What’s Next?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)’s share price gapped up prior to trading on Tuesday . The stock had previously closed at $43.65, but opened at $44.92. Agios Pharmaceuticals shares last traded at $44.7730, with a volume of 18,909 shares changing hands.

Wall Street Analyst Weigh In

AGIO has been the topic of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Agios Pharmaceuticals in a research note on Thursday. HC Wainwright reissued a “buy” rating and set a $56.00 price objective on shares of Agios Pharmaceuticals in a report on Thursday, September 4th. Wall Street Zen upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Scotiabank reduced their price target on shares of Agios Pharmaceuticals from $71.00 to $65.00 and set a “sector outperform” rating for the company in a research report on Monday, July 28th. Finally, Bank of America reduced their price target on shares of Agios Pharmaceuticals from $52.00 to $51.00 and set a “buy” rating for the company in a research report on Tuesday, July 22nd. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $57.25.

Agios Pharmaceuticals Stock Performance

The firm has a market capitalization of $2.66 billion, a PE ratio of -6.49 and a beta of 0.89. The firm’s 50-day moving average is $40.46 and its 200 day moving average is $36.90.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.78) earnings per share for the quarter, beating the consensus estimate of ($1.93) by $0.15. The firm had revenue of $12.90 million during the quarter, compared to the consensus estimate of $10.49 million. Agios Pharmaceuticals had a negative net margin of 895.86% and a negative return on equity of 28.35%. The firm’s revenue for the quarter was up 43.3% on a year-over-year basis. During the same period last year, the firm posted $16.22 EPS. As a group, equities analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current year.

Insider Transactions at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, insider Sarah Gheuens sold 3,302 shares of the firm’s stock in a transaction on Monday, October 27th. The stock was sold at an average price of $43.92, for a total transaction of $145,023.84. Following the completion of the transaction, the insider owned 61,727 shares of the company’s stock, valued at approximately $2,711,049.84. This trade represents a 5.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Cecilia Jones sold 3,651 shares of the business’s stock in a transaction on Friday, September 26th. The stock was sold at an average price of $36.77, for a total value of $134,247.27. Following the completion of the transaction, the chief financial officer directly owned 33,870 shares of the company’s stock, valued at approximately $1,245,399.90. This trade represents a 9.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 16,099 shares of company stock valued at $620,092 in the last ninety days. Corporate insiders own 4.93% of the company’s stock.

Institutional Trading of Agios Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AGIO. CWM LLC lifted its holdings in Agios Pharmaceuticals by 150.2% in the 1st quarter. CWM LLC now owns 1,659 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 996 shares in the last quarter. Victory Capital Management Inc. grew its holdings in shares of Agios Pharmaceuticals by 28.8% during the first quarter. Victory Capital Management Inc. now owns 8,784 shares of the biopharmaceutical company’s stock worth $257,000 after buying an additional 1,964 shares in the last quarter. GW&K Investment Management LLC raised its position in shares of Agios Pharmaceuticals by 19.6% in the first quarter. GW&K Investment Management LLC now owns 817,526 shares of the biopharmaceutical company’s stock valued at $23,954,000 after buying an additional 134,063 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of Agios Pharmaceuticals during the first quarter valued at approximately $1,601,000. Finally, TD Asset Management Inc lifted its stake in shares of Agios Pharmaceuticals by 7.5% during the first quarter. TD Asset Management Inc now owns 178,072 shares of the biopharmaceutical company’s stock valued at $5,218,000 after buying an additional 12,400 shares during the period.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.